Global peptide Phase III clinical drug summary

The peptide drug market has developed rapidly in recent years, and it is expected that the future peptide drug market will grow at a compound annual growth rate of 7.9%, reaching a market size of 49.5 billion US dollars by 2027, with huge room for growth. Many polypeptide drugs have entered phase III clinical trials.

Global peptide phase III clinical drug

In terms of research targets, according to the number of studies, GLP-1R, insulin, gp100, HER2, NTCP, GLP-1, GLP-2, TYR, WT1, CaN;

In terms of indications, mainly focused on cancer, type II diabetes, obesity, dry eye disease, heart failure, skin ulcer, surgery, type I diabetes, COVID-19;

In terms of the number of drugs, the research companies are mainly Novo Nordisk, Eli Lilly, IO Biotech, Polyphor, Takeda, OncoTherapy Science, Novartis, Shionogi, and Roche. 

(This article is reproduced with the authorization of <>)